Introduction
============

Vasculitis is a group of chronic inflammatory diseases in which the blood vessel is the target of an immune reaction. They can be idiopathic or due to infection, neoplasm, collagenoses or drugs. Rheumatoid arthritis (RA) is a chronic, progressive, systemic inflammatory disorder in which the joints are the primary target. Inflammatory central nervous system lesions are infrequent in RA. Cerebral rheumatoid vasculitis is an uncommon and serious complication of RA. Most reported cases have led to the death of the patient especially when cerebral vasculitis was associated with systemic rheumatoid vasculitis (Table [1](#T1){ref-type="table"}). The treatment of such patients must be effective. There is no standard treatment of this rare complication. We describe a patient with longstanding RA and isolated central nervous system vasculitis.

###### 

Literature review

  **Reference**                            **Age / Sex**   **Years**          **Pathologic diagnosis**     **Neurological manifestation**                 **Treatement**                  **Outcome**
  ---------------------------------------- --------------- ------------------ ---------------------------- ---------------------------------------------- ------------------------------- -------------
  Pirani and Bennet, 1951 \[[@B1]\]        22 Male         16                 CP and systemic vasculitis   Depressed MS, seizures                         NR                              Exitus
  Sokoloff and Bunim, 1957 \[[@B2]\]       64 Male         30                 CP and systemic vasculitis   NR                                             GC                              Exitus
  Johnson *et al*. 1959 \[[@B3]\]          37 Female       1 year 8 month     CP and systemic vasculitis   Seizures                                       GC                              Exitus
  Johnson *et al.* 1959 \[[@B3]\]          63 Male         3                  CP and systemic vasculitis   Hemiparesis                                    GC                              Exitus
  Steiner and Gellbloom, 1959 \[[@B4]\]    62 Male         20                 CP vasculitis                CN dysfunction, depressed MS                   GC                              Exitus
  Ouyang *et al*. 1967 \[[@B5]\]           58 Female       30                 CP vasculitis                Seizures, hemiparesis                          GC                              Exitus
  Ramos and Mandybur, 1975 \[[@B6]\]       63 Male         1                  CP and systemic vasculitis   Gerstmann syndrome                             NR                              Exitus
  Watson *et al*. 1977 \[[@B7]\]           54 Female       20                 CP vasculitis                CN dysfunction, aphasia, hemiparesis, ataxia   GC                              Exitus
  Kiss *et al.* 2006 \[[@B8]\]             51 Female       39                 CP and systemic vasculitis   Hemiparesis                                    GC immunoglobulin               Exitus
  Rodriguez *et al*. 2006 \[[@B9]\]        49 Female       10                 CP vascultis                 Aphasia, hemianopia                            GC cyclophosphamide             Improvement
  Rodriguez *et al*. 2006 \[[@B9]\]        70 Female       Recent diagnosis   CP vascultis                 Seizures                                       GC cyclophosphamide             Improvement
  Mrabet *et al.* 2007 \[[@B10]\]          59 Female       20                 CP vascultis                 Headache, diplopia, and gait disorders         High-dose GC cyclophosphamide   Improvement
  Caballol Pons *et al*. 2010 \[[@B11]\]   71 Female       15                 CP vascultis                 Headache, dysarthria                           High-dose GC                    Improvement
  Ohno *et al*. 1994 \[[@B12]\]            46 Female       16                 CP vasculitis                dysarthria and left hemiparesis                methotrexate therapy            Improvement
  Present case                             52 Female       9                  CP vascultis                 Headache                                       Intensification MTX therapy     Improvement

CN, cranial nerve; CP, cerebral parenchymal; GC, glucocorticoid; MTX, methotrexate; MS, mental status; NR, not reported.

Case presentation
=================

A 52-year-old North African Tunisian Caucasian woman was admitted with a six-week history of headache to hospital. She had been diagnosed with seropositive destructive RA nine years before, without any extra-articular manifestations. She received methotrexate 7.5mg per week, low doses of prednisone 7.5mg per day and anti-inflammatory drugs. She presented with a six-week history of bilateral temporal headaches. There was no fever or vomiting. Her body temperature was normal and her blood pressure was 120/60mmHg. Physical examination revealed typical joint deformities of RA, but with no subcutaneous nodules or skin lesions. Synovitis was noted at both wrists as well as at the second and third metacarpophalangeal joints of both hands. Her neurological examination was normal including her deep tendon and plantar reflexes. There was no evidence of meningitis or focal neurological signs. Her temporal pulses were brisk and symmetric. Laboratory tests revealed the following results: erythrocyte sedimentation rate of 27mm/hour, C-reactive protein of 14mg/l (normal: \<6) and hemoglobin of 14.9mg/DL. The white blood cell count was normal (8180/mm3) as were her platelets (380,000/mm3). Liver and kidney function tests were normal, as well as blood glucose levels. No obvious infection, disseminated intravascular coagulation, atlanto-axial dislocation or other collagen diseases were recognized by physical and blood examinations. Electrophysiological studies showed no evidence of peripheral nerve lesion or denervation. Tests were positive for rheumatoid factor (512UI/ml) and for antinuclear antibodies (1/640). Her serum complement, circulating immune complexes, and antineutrophil cytoplasm antibodies were normal. The fundus examination and the fluorescein angiography did not reveal any signs of vasculitis. Magnetic resonance imaging (MRI) of her brain with the T2 sequence showed high-intensity signal images at the frontal and parietal-cortico-subcortical junction suggesting hemispheric vasculitis (Figure [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Our patient had not had any severe neurological manifestation or any systemic non-neurological manifestation. She suffered only from persistent headache. Intensification of the methotrexate therapy (15mg per week) was enough to give a good outcome. Her headache disappeared in two weeks and there were no symptoms of meningitis or focal neurological signs after four months.

![**Cerebral magnetic resonance imaging.** T2-weighted image demonstrates high-intensity-signal involving white matter of two cerebral hemispheres.](1752-1947-6-302-1){#F1}

![**Cerebral magnetic resonance imaging.** T2 sequence, axial section demonstrates high signal in the subcortical area of the frontal and parietal lobes.](1752-1947-6-302-2){#F2}

Discussion
==========

It is well documented that collagen diseases, such as systemic lupus erythematosis (SLE), Sjögren's syndrome, and Behçet's disease, are often complicated by cerebrovascular disorders \[[@B13]\]; however, these seldom occur in RA \[[@B14]\]. The rate of occurrence of cerebral vasculitis in patients with RA is 1% to 8% \[[@B15]\]. Neurological manifestations in patients with RA can be due to inflammatory central nervous system lesions. They have been described traditionally in seropositive patients with long-standing, active and erosive RA, with subcutaneous nodules and extra-articular manifestations \[[@B11]\]. In our case, the RA was seropositive, active and erosive but the patient had no extra-articular signs especially no subcutaneous nodules. Cerebral vasculitis is usually associated with severe general signs as well as prominent extra-articular manifestations with minimal joint manifestations \[[@B10]\].

Our patient had no extra-articular manifestations other than those related to cerebral vasculitis. Neurological involvement in RA includes atlantoaxial subluxation, polymyositis, mononeuritis multiplex, peripheral neuropathy, rheumatoid nodules in the central or peripheral nervous system, and rheumatoid vasculitis causing stroke and/or neuropathy \[[@B13]\]. The neurological manifestations of rheumatoid cerebral vasculitis include focal signs such as hemiplegia, partial epilepsy, cranial nerve involvement, or visual field loss, altered consciousness, confusion, and cognitive impairment or dementia \[[@B10]\]. In our case, vasculitis is revealed by severe and persistent headache which is a common symptom and may suggest giant cell arteritis, particularly as this condition can occur in patients with RA \[[@B16]\]. The presence of temporal pulse and the normality of the funduscopy, especially the absence of vasculitis signs, militated against giant cell arteritis. Patients with a diagnosis of pathological vasculitis involving the cerebral parenchyma are infrequent \[[@B1]-[@B9]\]. Eight specified cases were considered to show isolated cerebral vasculitis, and six other cases were associated with symptoms indicating systemic rheumatoid vasculitis. The present case report is similar to the majority of previously reported cases in that our patient displayed an isolated central nervous system vasculitis. We did not detect any other visceral vasculitis. Our patient had a long-standing history of RA, which required steroid therapy and the diagnosis of rheumatoid cerebral vasculitis was made by cerebral MRI. Other causes of cerebral vasculitis were eliminated as far as possible based on past history, physical findings, clinical data, laboratory studies, and response to the therapy.

Biopsy of the brain is not systematic. Actually, neuroradiological analysis can be useful for detecting cerebral vascular disorders. In our case, T2-weighted MRI showed high signal intensity in the frontal and parietal cortico-subcortical junction, however, no obvious abnormality was detected on T1-weighted MRI. Glucocorticoids at different dosages and administrations have been reported in the treatment of central nervous system rheumatoid vasculitis. Several alternatives such as azathioprine \[[@B17]\], intravenous immunoglobulins \[[@B8]\] and cyclophosphamide \[[@B9],[@B18]\] are available for patients with corticosteroid-resistant or refractory vasculitis. In our case, the intensification of the methotrexate therapy was enough to give a good outcome, especially as there were no symptoms of systemic vasculitis. Tatsuharu Ohno \[[@B12]\] reported the successful management of cerebral vasculitis in a 46-year-old woman who presented with sudden dysarthria and left hemiparesis after the initiation of the methotrexate therapy \[[@B12]\]. Although high doses of glucocorticoid and cyclophosphamide were used, the cases associated with systemic rheumatoid vasculitis had the worst prognosis.

Conclusions
===========

Neurological involvement in rheumatic disease is associated with high morbidity and, in some cases, can be life-threatening. Early assessment and a high index of suspicion for recognized complications are essential in managing such patients. Although serious neurological complications in rheumatic disease appear to be rare, few studies have been conducted on their prevalence. Studies of larger cohorts of patients in multi-center settings are required to assess the management of such patients more fully.
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